W8MD Diet | COVID-19 portal | Vitamin D | Vaccine | Keto

WikiMD is the world's largest medical encyclopedia with
14,009 pages, 4,159,404 edits & 43,392,504 views.

Free unbiased diet, health and wellness info!


From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search



A drug used to treat chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used in some newly diagnosed patients. It is also used in patients who cannot be treated with or have not gotten better after other treatment. It is also being studied in the treatment of other types of cancer. Bosutinib blocks BCR-ABL and other proteins, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Bosulif.

Information about Bosutinib

Bosutinib is a dual kinase inhibitor of both the BCR-ABL and Src tyrosine kinases and is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia.    

Liver safety of Bosutinib

Bosutinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury.

Mechanism of action of Bosutinib

Bosutinib (boe sue’ ti nib) is an orally available, small molecule inhibitor of the BCR-ABL tyrosine kinase receptor, which is the product of a fusion gene resulting from the reciprocal translocations between chromosomes 9 and 22 that characterize the Philadelphia chromosome of chronic myelogenous leukemia (CML).  The abnormal tyrosine kinase receptor is constitutively expressed and causes unregulated cell growth and proliferation in myeloid cells.  Inhibition of the receptor can lead to dramatic reversal of progression of leukemia, although sometimes limited by the development of tumor resistance caused by mutations in the kinase.  Bosutinib was the fourth BCR-ABL tyrosine kinase receptor inhibitor approved for use in cancer chemotherapy (after imatinib, dasatinib and nilotinib) and, like many of the BCR-ABL tyrosine kinase inhibitors, also has some activity against the abnormal tyrosine kinase (c-Kit) that is found in gastrointestinal stromal tumors (GIST).  Bosutinib also has activity against the receptors for platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). 

FDA approval information for Bosutinib

Bosutinib received approval for use in the United States in 2012.  Current indications are for adult patients with Philadelphia chromosome-positive CML in the chronic, accelerated or blast stages and with resistance or intolerance to previous therapy. 

Dosage and administration for Bosutinib

Bosutinib is available in tablets of 100 and 500 mg under the brand name Bosulif.  The typical dose is 500 mg orally once daily, with dose adjustment based upon tolerance and efficacy. 

Side effects of Bosutinib

Side effects include fatigue, nausea, diarrhea, abdominal pain, thrombocytopenia, anemia, fever and rash.  Uncommon, but potentially severe side effects include hypersensitivity reactions, infections and bone marrow suppressionAlphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Bosutinib

Reviews for Bosutinib

Learn more about Bosutinib

Latest research - Bosutinib

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Bosutinib is a stub. If you are familiar with the topic Bosutinib, you can help us. Paid editors welcome!


Bosutinib is part of WikiMD's free ^articles!

^Bosutinib (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available